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Comparison of losartan and amlodipine in renally impaired
hypertensive patients. Effects of losartan and amlodipine on
blood pressure and albuminuria were compared in a randomized,
double-blind, parallel trial involving 48 patients with essential
hypertension (sitting diastolic blood pressure between 95 to 115
mm Hg) and impaired renal function (creatinine clearance of 30
to 60 ml/min/1.73 m2). After four weeks of placebo administra-
tion, patients were stratified according to baseline albuminuria (,
or $ 300 mg/min) and randomized to once-daily treatment with
losartan 50 mg (N 5 24) or amlodipine 5 mg (N 5 24) for 12
weeks. Titration to losartan 50 mg/hydrochlorothiazide (HCTZ)
12.5 mg or amlodipine 10 mg was possible at weeks 3 or 6 for
patients having an inadequate blood pressure response. After 12
weeks of treatment, the mean decreases in sitting diastolic and
systolic blood pressures were significantly larger in the losartan
group (218.1 6 7.2 and 227.7 6 15.2 mm Hg) than in the
amlodipine group (212.4 6 7.5 and 216.3 6 12.1 mm Hg; P 5
0.009 and P 5 0.008, respectively). The greater antihypertensive
response to losartan was not influenced by the initial degree of
albuminuria. The losartan and amlodipine regimens were well-
tolerated. Baseline levels of albuminuria were reduced after 12
weeks of losartan treatment (median change of 229.5 mg/min),
while amlodipine therapy was associated with a median increase
(48.4 mg/min) in this renal marker at week 12. The treatment
difference was statistically significant (P 5 0.021). These results
indicate that losartan 50 mg, administered alone or in combina-
tion with HCTZ 12.5 mg, is more effective than amlodipine 5/10
mg in lowering blood pressure and albuminuria in patients with
essential hypertension complicated by impaired renal function.
High blood pressure, even modest elevations, has been
shown to be a strong, independent risk factor for end-
stage renal disease [1]. Losartan potassium (losartan;
COZAARy) is a potent and selective blocker of the AT1
subtype of angiotensin II receptors. In patients with essen-
tial hypertension, once daily administration of losartan
administered alone at doses of 50 and 100 mg or in
combination with hydrochlororthiazide (HCTZ) 12.5 mg
has been shown to be well-tolerated and efficacious in
lowering blood pressure throughout the 24-hour dosing
interval [2, 3]. In human kidneys, angiotensin II receptors
are predominantly of the AT1 subtype [4], and losartan
treatment has been shown to reduce albuminuria among
individuals with renal disease at least as effectively as the
angiotensin converting enzyme (ACE) inhibitor, enalapril
[5].
The present 12 week trial was designed to compare the
effects of losartan on blood pressure and metabolic param-
eters indicative of renal function with those of amlodipine,
a widely used and effective antihypertensive agent belong-
ing to the dihydropyridine class of calcium antagonists.
METHODS
Study design
The study consisted of a pre-placebo period of at least
one week duration, a four-week placebo baseline period
and a 12-week active treatment period in which eligible
patients were randomized to once daily treatment with
losartan 50 mg or amlodipine 5 mg. Randomization was
performed in a stratified manner within each investiga-
tional site according to baseline albuminuria (, 300 or $
300 mg/min). Titration to losartan 50 mg plus hydrochlo-
rothiazide (HCTZ) 12.5 mg or amlodipine 10 mg was
indicated for patients whose sitting diastolic blood pressure
(SiDBP) remained at or above 106 mm Hg at week 3 or at
or above 90 mm Hg at week 6. All trial medications were
administered once daily in the morning.
Patient population
Forty-eight male or female patients with essential hyper-
tension and impaired renal function, defined as a creatinine
clearance between 30 and 60 ml/min/1.73 m2, were re-
cruited at seven investigational sites in Italy, Norway,
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Portugal and Spain. Informed consent was obtained from
each patient prior to study participation, as was ethical
committee approval. All patients provided informed con-
sent. All patients were at least 18 years of age, and had no
concurrent medical conditions or therapy that might affect
blood pressure. In particular, no patient had a diagnosis of
acute renal failure, known renal arterial stenosis, uncon-
trolled diabetes mellitus or a clinically significant serum
potassium, AST or ALT abnormality. Prior to single-blind
treatment with placebo, all current antihypertensive medi-
cation was discontinued for at least seven days (4 weeks for
ACE inhibitor drugs). Only patients whose trough SiDBP
(that is, 22 to 26 hr after the preceding morning dose) was
between 95 and 115 mm Hg after two and four weeks of
placebo therapy qualified for randomization to double-
blind therapy.
Study variables
Trough blood pressure, heart rate and body wt were
measured at three week intervals during the active treat-
ment period. Blood was sampled, and a fresh morning
urine sample was provided after one week of placebo
administration and after 6 and 12 weeks of active treatment
for routine fasting hematology, blood chemistry and urinal-
ysis evaluations. Twenty-four-hour urine collections were
performed at weeks 24 and 23 of the placebo period and
twice at week 12, separated by a two to three day interval,
for determination of urine volume and excretion of albu-
min and creatinine. All laboratory tests, except for tests
used to evaluate initial eligibility and monitor patient
safety, were performed by a central laboratory.
Statistical analysis
All patients who had a baseline and at least one post-
randomization measurement were included in the analyses
of blood pressure and laboratory variables. The last double-
blind measurements of withdrawn patients were carried
forward to subsequent time points.
Changes from baseline in trough sitting diastolic
(SiDBP) and systolic (SiSBP) blood pressures at week 12
were analyzed for comparative efficacy between treatment
groups using a least squares analysis of the means based
upon an analysis of variance (ANOVA) that included
treatment, center and stratum (baseline microalbuminuria)
as main effects and terms for treatment-by-center and
treatment-by-stratum interactions. Within group compari-
sons were assessed by means of a one-sample t-test. Due to
the non-normality of the 24-hour urine data, changes from
baseline to week 12 were analyzed using the Wilcoxon
signed-ranked test.
The antihypertensive response to treatment was catego-
rized as: SiDBP , 90 mm Hg; SiDBP $ 90 mm Hg and a
decrease from baseline of $ 10 mm Hg; and SiDBP $ 90
mm Hg and a decrease from baseline of , 10 mm Hg. The
responses were compared between the treatment groups
using MuCullagh’s method for ordered categorical data
including treatment and stratum as main effects.
Statistical significance was defined as a P value # 0.05,
two-sided.
RESULTS
Patient characteristics
Of the 48 patients enrolled, 12 men and 12 women were
randomized to the losartan group and 19 men and 5 women
were randomized to the amlodipine group. The two groups
were similar with respect to age, race, coexistence of
diabetes, severity of hypertension, SiDBP at baseline and
median albuminuria at baseline (Table 1). All patients in
the losartan group completed the 12 weeks of active
treatment. A total of five patients in the amlodipine group
discontinued prematurely; two were withdrawn for clinical
adverse experiences, one discontinued for insufficient re-
sponse and two were withdrawn for major protocol viola-
tions.
Antihypertensive efficacy
Except for one patient in the amlodipine group who did
not have post-randomization blood pressure measure-
ments, data from all randomized patients were included in
the efficacy analyses. While statistically significant reduc-
tions from baseline in trough SiDBP and SiSBP at week 12
were observed in both treatment groups, the magnitude of
the reductions were significantly larger following losartan
therapy compared to treatment with amlodipine (P 5 0.009
for SiDBP and P 5 0.008 for SiSBP; Table 2). No signifi-
cant interactions between study center or albuminuria
stratum could be established for either blood pressure
variable. Figure 1 displays the mean change from baseline
in SiDBP and SiSBP at week 12 as a function of baseline
albuminuria (, 300 or $ 300 mg/min). For both subgroups,
the blood pressure lowering response was consistently
greater in the losartan group.
Half (N 5 12) of the patients randomized to losartan
Table 1. Demographics and baseline characteristics
Characteristic Losartan Amlodipine
Patients N 24 24
Male 12 19
Female 12 5
Age years
Mean (SD) 55.7 (12.2) 54.9 (12.1)
Race
Caucasian 24 24
Coexistence of diabetes 9 11
SiDBP mm Hg
Mean (SD) 101.4 (6.0) 101.2 (6.5)
Albuminuria mg/min
Median 359.2a 396.7
, 300 mg/min 10 10
$ 300 mg/min 12 14
a For two patients the baseline albuminuria was not recorded
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required the addition of HCTZ 12.5 mg after three (N 5 4)
or six weeks (N 5 8). In the amlodipine group, nine
patients were titrated to 10 mg after three (N 5 1) or six
weeks (N 5 8) because they did not reach the desired goal
of trough SiDBP , 90 mm Hg. After 12 weeks of treat-
ment, 96% of losartan-treated patients and 87% of amlo-
dipine-treated patients had a SiDBP , 90 mm Hg or a
decrease in SiDBP from baseline of least 10 mm Hg
(between-group difference, P . 0.10).
Effects on renal parameters
Table 3 summarizes the mean baseline and median and
mean changes from baseline in albuminuria and creatinine
clearance at week 12 for the losartan and amlodipine
groups. Losartan therapy was associated with a reduction in
albuminuria after 12 weeks, while amlodipine therapy was
associated with median increase in this marker of renal
function. The between treatment difference was statistically
significant (P 5 0.021). The change in creatinine clearance
after 12 weeks of treatment did not differ significantly
between the groups.
Safety and tolerability
Seven patients (29%) in the losartan group and five
(21%) in the amlodipine group reported at least one
clinical adverse experience during the 12-week active treat-
ment period. Dizziness and headache (one report each)
were the only adverse experiences considered at least
possibly related to active treatment in the losartan group.
None of the adverse experiences in the losartan group were
considered serious, and no patient withdrew prematurely
from losartan therapy because of an adverse experience. In
the amlodipine group, there were three reports of edema,
and one report each of tachycardia, cerebral edema and
headache considered at least possibly drug-related. There
was one serious adverse experience in the amlodipine
group (myocardial infarction). This patient, and an addi-
tional patient who experienced tachycardia, headache and
cerebral edema two days after beginning amlodipine ther-
apy, discontinued the study prematurely due to their ad-
verse experiences.
There were no serious adverse laboratory experiences.
Mean changes in serum potassium levels or serum lipid
profiles (total cholesterol, HDL-cholesterol and triglycer-
ides) after 12 weeks of active treatment were small and did
not differ significantly between the losartan and amlodipine
groups.
DISCUSSION
Patients with high blood pressure and renal disease are a
high-risk population since elevated blood pressure is asso-
ciated with a more rapid progression of renal failure [6].
Several interventional studies have demonstrated that this
progression can be attenuated by effective control of blood
pressure with antihypertensive medication [7, 8]. According
to the recent report from the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure, patients with renal insufficiency (that is,
those with a high degree of proteinuria) should be treated
to a lower blood pressure goal [9]. In the present study of
patients with impaired renal function complicated by mild
to moderate hypertension, the angiotensin II blocker losar-
tan produced clinically meaningful reductions in sitting
diastolic and systolic blood pressure that averaged 18 and
28 mm Hg, respectively, after 12 weeks. The blood pressure
response to losartan was comparable across the two stra-
tum of albuminuria (, 300 or $ 300 mg/min). Moreover,
the reductions seen following once daily treatment with
losartan 50 mg or losartan 50 mg/HCTZ 12.5 mg were
statistically superior to those observed following once daily
treatment with amlodipine 5 to 10 mg.
Albuminuria is a strong predictor for the development of
overt renal and cardiovascular events. Reduction of albu-
minuria has been considered as a subrogate marker for
renal protection [10, 11]. Although the reduction in pro-
teinuria can be related to lowering blood pressure, it
appears that drugs blocking the renin-angiotensin-aldoste-
rone system have an effect that is beyond their antihyper-
tensive effect. This has been clearly demonstrated with
ACEIs [12, 13]. An adjustment by blood pressure was not
made in this study, however, results of the present trial
confirm the ability of losartan to reduce albuminuria. For
example, losartan was previously shown to be comparable
to enalapril in decreasing albuminuria and lowering blood
pressure in patients with renal disease and hypertension
[14]. Furthermore, results of the present trial demonstrated
that losartan was significantly more effective than amlodip-
ine in reducing the urinary excretion of albumin. These
findings are in agreement with those reported by Holdass
Table 2. Mean change in trough sitting diastolic and systolic blood
pressures at week 12
Parameter
Losartan
(N 5 24)
Amlodipine
(N 5 23)
SiDBP
Baseline mean (SD) 101.4 (6.0) 100.8 (6.4)
Week 12 mean (SD) 83.3 (7.0) 88.5 (8.5)
Change from baseline: mean (SD) 218.1 (7.2)b 212.4 (7.5)b
Treatment difference
Least square mean (95% CI) 25.8 (210.1%, 21.5%)
P valuea 0.009
SiSBP
Baseline mean (SD) 165.2 (15.2) 161.3 (16.8)
Week 12 mean (SD) 137.5 (18.8) 145.0 (16.1)
Change from baseline: mean (SD) 227.7 (15.2)b 216.3 (12.1)b
Treatment difference
Least square mean (95% CI) 211.3 (219.5%, 23.1%)
P valuea 0.008
Abbreviations are: SiDBP, sitting diastolic blood pressure; SiSBP,
sitting systolic blood pressure.
a P value for pairwise comparison; ANOVA
b Significant change from baseline, P , 0.001; within treatment com-
parison (t-test)
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and colleagues [15], who showed that urinary albumin
excretion was significantly decreased in patients with non-
diabetic renal disease following four weeks of treatment
with losartan but was increased a comparable course of
amlodipine treatment. Results of animal and clinical stud-
ies on the ability of calcium channel blockers to retard
progression to renal failure have been variable and gener-
ally less striking than those with ACE inhibitors [16, 17].
Losartan alone or with the addition of a low dose of
hydrochlorothiazide did not significantly alter creatinine
clearance in this study. The present results, coupled with
those from a previous investigation showing that losartan
does not adversely alter renal hemodynamics [18], suggest
a nephroprotective effect for losartan in patients with
essential hypertension.
No differences in tolerability between losartan and am-
lodipine were found in the present study. The favorable
safety profile of losartan observed in this study is consistent
with the overall safety profile seen in studies of hyperten-
sive patients [19]. Across this large cohort involving over
2990 patients, dizziness was the only side effect reported as
drug-related that occurred in patients receiving losartan at
an incidence greater than placebo of at least 1%. In
particular, cough and angioedema, adverse experiences
noted with ACE inhibitors and thought to be related to
bradykinin potentiation, are infrequently reported during
losartan therapy.
In summary, once daily administration of losartan 50 mg,
administered alone or in combination with HCTZ 12.5 mg,
was more effective than amlodipine 5/10 mg in lowering
blood pressure and albuminuria in patients with essential
hypertension complicated by impaired renal function.
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